# Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

> **NCT03130764** · PHASE2 · WITHDRAWN · sponsor: **Columbia University**

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03130764
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-03
- **Primary completion:** 2017-11-30
- **Final completion:** 2017-11-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI Transferred
- **Last updated:** 2017-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03130764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03130764, "Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03130764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*